Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or Botanical

or Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism)

Use the filters below to narrow your results.

None (24) · Anafranil (1) · Aurorix (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Nuplazid (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1)

Apomorphine and nuciferine; dopaminergic activity (1) · Contains atropine, scopolamine, hyoscyamine (1) · Contains bufotenin and DMT (1) · Contains harmine, harmaline, tetrahydroharmine (1) · Contains ibogaine; kappa-opioid agonist (1) · Contains LSA (2) · Contains mescaline (2) · Contains muscimol and ibotenic acid (1) · Contains psilocybin and psilocin (1) · Contains salvinorin A (1) · DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) · DMT-containing plant used in psychedelic preparations (1) · Irreversible non-selective MAO inhibitor (3) · Kavalactones; GABAA modulator; sigma receptor activity (1) · Mechanism incompletely understood (1) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Partial MAOI; anticholinergic effects (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Potent mu-opioid receptor agonist (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Reversible inhibitor of MAO-A (1) · Reversible MAO-A inhibitor; beta-carboline (1) · Reversible MAO-A inhibitor; NMDA antagonist; beta-carboline (1) · Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak serotonin reuptake inhibitor; beta-carboline (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)

None (41) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1)

None (41) · 25 mg (1) · 34 mg PO once daily (1)

None (41) · 10 mg, 34 mg capsules/tablets (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1)

None (41) · 200 mg/d (1) · 34 mg/d (1)

None (40) · Oral (3)

None (40) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Benefit over weeks of dosing (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (40) · Chronic daily dosing (1) · Daily dosing (1) · Long (1)

None (40) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~57 hours (parent), ~200 h (active metabolite) (1)

None (40) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Not characterized; oral dosing once daily (1) · ~50% (highly variable) (1)

None (40) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Limited data; avoid (1)

None (40) · Rx-only (1) · Rx-only in US (1) · Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1)